MK-5108 Size:Solid 10 mg The histone deacetylase inhibitor MS-275

The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1

and 50 mg/kg dose groups

InChi: InChI=1S/C23H26F2N2O4/c1-14(26-19(28)12-15-10-17(24)13-18(25)11-15)21(29)27-20(16-8-6-5-7-9-16)22(30)31-23(2

(2013) Sci Transl Med

LY294002 provides a starting point for the generation of bromodomain inhibitors tapping the chemical space of kinase antagonists

MK-5108 Size:Solid 10 mg The histone deacetylase inhibitor MS-275MK 5108, also known as VX689, is a novel small molecule with potent inhibitory activity against Aurora A kinase. MK 5108 specifically inhibited Aurora A kinase in a panel of protein kinase assays. MK 5108 also induced phosphorylated Histone H3 in skin and xenograft tumor tissues in a nude rat xenograft model. MK 5108 inhibited growth of human tumor cell lines in culture and in different xenograft models. MK 5108 is currently tested in clinical trials